Latest news with #LeftVentricularAssist
News18
2 days ago
- Health
- News18
Heart Failure In Your 30s? Understanding The Myths, Risks, And Modern Fixes
Indians are prone to developing heart problems at a younger age compared to those in the West. One of the most common reasons behind this trend is the fast-paced modern lifestyle. If you're in your 20s or 30s, you might only think about your heart during an intense workout or when trying to hit a new personal best. But this tireless muscle works every second of your life, quietly powering your every moment. It deserves more than just an occasional thought. No matter your age, your heart needs consistent care. According to the World Health Organisation, cardiovascular diseases (CVDs) affect around 17.9 million people annually. In India, the situation is particularly alarming: we account for 60% of the world's heart disease cases, and Indians tend to develop heart problems at a younger age than populations in Western countries. Dr. Rajneesh Malhotra, Chairman & Head, Cardio Thoracic and Vascular Surgery, Max Super Speciality Hospital, Saket, Delhi, warns, 'With the speed and direction of our lives in the present time, stressors and cardiovascular diseases can only be anticipated to grow, unless we take a conscious step towards altering the path of our cardiac health." Understanding Heart Failure Heart failure occurs when the heart becomes too weak or stiff to pump blood efficiently. It can result from conditions such as high blood pressure, blocked arteries, heart rhythm problems, or congenital defects. The body tries to compensate by enlarging the heart, pumping faster, or diverting blood to vital organs, but these measures are temporary. In India, younger adults are increasingly affected, often due to lifestyle choices: chronic stress, poor sleep, unhealthy diets, and lack of exercise all contribute to risk. Lifestyle and Medical Interventions Early detection is critical. Managing blood pressure, blood sugar, cholesterol, and stress levels, along with regular exercise and adequate sleep, can dramatically lower the risk. For those already diagnosed, medicines, dietary adjustments, and cardiac rehabilitation programmes can slow disease progression. The Role of Technology For patients with advanced heart failure, a heart transplant is often the gold standard, but long donor waitlists and health constraints limit access. Left Ventricular Assist Devices (LVADs), surgically implanted pumps that help circulate blood, are transforming treatment. Once seen as a short-term 'bridge" to transplant, LVADs are now used as long-term, 'destination" therapy. Recent innovations have made these devices smaller, safer, and more efficient, reducing complications and improving quality of life. Patients can return to many normal activities, with survival rates steadily improving. For many, LVADs offer not just extended life, but renewed independence and hope. First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Wire
24-04-2025
- Business
- Business Wire
CorWave Announces Successful Completion of 6-Month Chronic In Vivo Study, Paving the Way for Clinical Trial Initiation
CLICHY, France--(BUSINESS WIRE)--CorWave, a medical device company dedicated to the fight against heart failure, announces new preclinical results of its implantable heart pump. CorWave's in vivo studies demonstrated the pump's successful operation for six months. Additionally, nine chronic ovine implants were conducted for 60 days, without chronic anticoagulant therapy. There was no device failure during the studies and no sign of thrombosis at explant. The CorWave device operated in pulsatile mode, synchronizing with the native heart rate. These studies underpin the device's thromboresistance, stable algorithm, and hemocompatibility. These significant milestones mark the final stage of CorWave's preclinical development, paving the way for its First-In-Human study. CorWave is developing an implantable LVAD (Left Ventricular Assist Device) driven by its proprietary breakthrough wave membrane pump technology. This unique pumping mechanism, combined with a smart algorithm, enables the CorWave pump to adapt its flow to patients' activity levels and preserve physiological balance, aiming to reduce adverse events and improve quality of life. 'This technology has the potential to shape the future of long term mechanical circulatory support. It can overcome current limitations of rotary blood pumps and create real smart and adaptive circulatory support: the results of the preclinical studies were excellent. Beyond the objectives of the study, additional animals were successfully followed up for six months with convincing pump performance. I am excited to see this new device taking the next steps into clinical practice.' commented Dr. Martin Strueber, cardiac surgeon who supported the company in the preclinical development. 'CorWave's novel self-adaptive, smart LVAD has demonstrated excellent preclinical results, with no device-related failures and complications. Surgical implantations were uneventful and intuitive. The newly introduced control algorithm allowed synchronous support, either in co-pulsation or counter-pulsation mode, and operated reliably throughout the study. Safety and feasibility have been successfully demonstrated, paving the way for clinical trials,' added Dr. Sebastian Schulte Eistrup, cardiac surgeon who was also involved in the in vivo studies. 'These results not only meet the highest standards in the LVAD industry but also indicate potential clinical advantages over rotary blood pumps that have been in use since the late 1990s. Following these significant milestones, the team is now actively preparing for the clinical introduction of the device,' concluded Louis de Lillers, CEO. About CorWave: CorWave is a French company that develops and manufactures innovative cardiac assist devices. The CorWave undulating membrane is a breakthrough technology that differs from today's commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave's membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by the start-up studio MD Start and is funded by renowned investors including Bpifrance, EIC Fund, Financière Arbevel, M&L Healthcare, Novo Holdings, Seventure Partners, Sofinnova Partners, Ysios Capital and Vlerick Group. The company has secured over €80 million in equity capital and employs over eighty people. In October 2023, after more than ten years of research and development, CorWave scaled up to an industrial level with the inauguration of its urban factory in Clichy. Equipped with state-of-the-art technology, the facility is designed to produce up to 1,000 pumps per year, representing a potential revenue of approximately €100 million.
